Jacobi Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Jacobi Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-21	Closed	-$1K	–	1412
2020 Q4	$1K	Hold	21	–	–	﹤0.01%	1240
2020 Q3	$1K	Sell	21 -160	-88%	-$10.9K	﹤0.01%	1189
2020 Q2	$13K	Hold	181	–	–	﹤0.01%	731
2020 Q1	$8K	Buy	181 +21	+13%	+$1.19K	﹤0.01%	742
2019 Q4	$10K	Hold	160	–	–	﹤0.01%	747
2019 Q3	$10K	Hold	160	–	–	﹤0.01%	727
2019 Q2	$11K	Hold	160	–	–	﹤0.01%	724
2019 Q1	$13K	Hold	160	–	–	﹤0.01%	659
2018 Q4	$14K	Sell	160 -401	-71%	-$42.7K	﹤0.01%	609
2018 Q3	$96K	Buy	+561	New	+$84.6K	0.03%	335

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Jacobi Capital Management's LGND Position: Q1 2021 in Review

Jacobi Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2021, closing a stake of 21 shares — an estimated $1K sold.

Jacobi Capital Management first reported a position in LGND in Q3 2018 and held it in 10 quarters. The position peaked at $96K in Q3 2018. 228 funds tracked by Wall St. Rank hold LGND as of Q1 2021.

Jacobi Capital Management reported no remaining Ligand Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Jacobi Capital Management sold 21 Ligand Pharmaceuticals shares in Q1 2021, an estimated $1K.
Jacobi Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2018 and held it in 10 quarters.
Jacobi Capital Management's Ligand Pharmaceuticals position peaked at $96K in Q3 2018.
228 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2021.

Based on Jacobi Capital Management's 13F filing for Q1 2021, filed 11 May 2021.